FDA Approves Polatuzumab Vedotin-piiq Plus R-CHP For Certain Types of Diffuse Large B-cell Lymphoma
April 20th 2023In a phase 3 trial, the risk of disease progression, relapse, or death was reduced by 27% with polatuzumab vedotin-piiq plus R-CHP compared with R-CHOP in adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma.
Read More
FDA Approves Expanded Indication for Hyqvia to Treat Pediatric Primary Immunodeficiency
April 12th 2023During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.
Read More
FDA Accepts Supplemental New Drug Application for Encorafenib, Binimetinib Combination in NSCLC
April 6th 2023The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.
Read More